• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Sonder Capital Appoints Kate Garrett as Managing Partner to Lead Next Generation of Growth

    4/2/24 8:00:00 AM ET
    $ISRG
    $PRCT
    $SWAV
    Industrial Specialties
    Health Care
    Medical/Dental Instruments
    Health Care
    Get the next $ISRG alert in real time by email

    Co-founders and industry luminaries Dr. Fred Moll and Jay Watkins will assume the newly created role of Co-chair as firm closes its latest fund, Futures II

    Sonder Capital, a leading venture capital firm focused on identifying teams and technologies that will transform healthcare, today announced the appointment of firm Co-founder Kate Garrett as Managing Partner. In this pivotal role, Garrett will spearhead Sonder's next phase of growth as the firm closes Sonder Futures II, its second early stage fund.

    With Garrett becoming Managing Partner, Sonder Co-founders and industry luminaries Fred Moll, M.D. and Jay Watkins will maintain their roles as partners and assume the newly created positions of Co-chairs to help guide and support future growth. This strategic move comes as Sonder continues to accelerate innovation, foster innovative leadership, and invest in the next generation of transformative healthcare technologies.

    A respected and well-known leader in the healthcare innovation community, Garrett serves on the board of Sonder portfolio companies Spirair, BRIUS Technologies, Ziteo, and Neptune Medical. She brings nearly two decades of experience as a successful inventor, founder, and operator across a wide spectrum of companies from early-stage startups to multinational organizations. Among her many achievements, Garrett co-founded and led Ciel Medical in the invention, development and commercialization of critical care products for ventilated patients. The company was acquired by Vyaire Medical in 2017. She also serves as Assistant Director of the Stanford Biodesign Innovation Fellowship, where she guides emerging inventors and entrepreneurs in the discovery and development of breakthrough technologies that solve significant unmet healthcare needs.

    "I am honored to have the opportunity to lead our partnership into our next phase of development," said Garrett. "With unsustainable costs and an aging patient population, the fundamental need for better healthcare solutions is as great as ever. These are the types of challenges Sonder is working to address."

    "Kate is the ideal leader for our next generation of growth and innovation," said Watkins. "She is an extraordinary, empathetic team builder who is respected by investors and entrepreneurs alike. Her passion for scaling technologies and developing leaders is critical to our portfolio and firm's success," he said.

    "As we close our second fund, it's crucial for us to have a leader who can collaborate with our partners to build a dynamic infrastructure that will further support and accelerate our growth," said Moll. "Kate has a unique blend of capabilities with her success as an inventor, founder, and operator, and her prominence as a leader and mentor in the healthcare innovation community. Her skills and vision will play a key role in taking us through our next phase of growth," he said.

    About Sonder Capital

    Sonder's team of veteran investors, innovators, founder-operators, and company builders is known not only for their individual achievements, but also for their collective success in creating, funding, and leading private and public companies that have transformed healthcare for millions of patients globally — including Intuitive Surgical (NASDAQ:ISRG), Shockwave Medical (NASDAQ:SWAV), Procept Biorobotics (NASDAQ:PRCT), Auris Health, and Reflexion Medical, among others. Sonder's extensive network of limited partners is global and includes industry leaders, high-net-worth individuals, and leading family offices focused on investing in game-changing healthcare technologies. Sonder Capital was co-founded in 2019 by healthcare luminaries Jay Watkins and Fred Moll, M.D.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20240401500277/en/

    Get the next $ISRG alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ISRG
    $PRCT
    $SWAV

    CompanyDatePrice TargetRatingAnalyst
    Intuitive Surgical Inc.
    $ISRG
    7/23/2025Buy → Hold
    Erste Group
    PROCEPT BioRobotics Corporation
    $PRCT
    7/9/2025$70.00Overweight
    Stephens
    PROCEPT BioRobotics Corporation
    $PRCT
    7/7/2025Perform
    Oppenheimer
    Intuitive Surgical Inc.
    $ISRG
    6/9/2025$440.00Hold → Sell
    Deutsche Bank
    Intuitive Surgical Inc.
    $ISRG
    6/5/2025Hold → Buy
    Erste Group
    PROCEPT BioRobotics Corporation
    $PRCT
    12/2/2024$105.00Overweight
    Morgan Stanley
    Intuitive Surgical Inc.
    $ISRG
    12/2/2024$522.00 → $650.00Equal-Weight → Overweight
    Morgan Stanley
    PROCEPT BioRobotics Corporation
    $PRCT
    11/14/2024$95.00Hold
    Jefferies
    More analyst ratings

    $ISRG
    $PRCT
    $SWAV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Intuitive Surgical downgraded by Erste Group

    Erste Group downgraded Intuitive Surgical from Buy to Hold

    7/23/25 8:54:24 AM ET
    $ISRG
    Industrial Specialties
    Health Care

    Stephens initiated coverage on PROCEPT BioRobotics with a new price target

    Stephens initiated coverage of PROCEPT BioRobotics with a rating of Overweight and set a new price target of $70.00

    7/9/25 8:44:45 AM ET
    $PRCT
    Medical/Dental Instruments
    Health Care

    Oppenheimer initiated coverage on PROCEPT BioRobotics

    Oppenheimer initiated coverage of PROCEPT BioRobotics with a rating of Perform

    7/7/25 8:02:36 AM ET
    $PRCT
    Medical/Dental Instruments
    Health Care

    $ISRG
    $PRCT
    $SWAV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Desai Antal Rohit exercised 26,749 shares at a strike of $1.33, increasing direct ownership by 318% to 35,152 units (SEC Form 4)

    4 - PROCEPT BioRobotics Corp (0001588978) (Issuer)

    8/15/25 4:53:14 PM ET
    $PRCT
    Medical/Dental Instruments
    Health Care

    Director Moll Frederic H bought $785,138 worth of shares (20,000 units at $39.26), increasing direct ownership by 2% to 863,159 units (SEC Form 4)

    4 - PROCEPT BioRobotics Corp (0001588978) (Issuer)

    8/14/25 4:18:26 PM ET
    $PRCT
    Medical/Dental Instruments
    Health Care

    EVP, CLO, CORP. SEC. Nouri Alaleh exercised 11,000 shares at a strike of $4.52, increasing direct ownership by 18% to 72,473 units (SEC Form 4)

    4 - PROCEPT BioRobotics Corp (0001588978) (Issuer)

    8/14/25 4:15:56 PM ET
    $PRCT
    Medical/Dental Instruments
    Health Care

    $ISRG
    $PRCT
    $SWAV
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $ISRG
    $PRCT
    $SWAV
    SEC Filings

    View All

    $ISRG
    $PRCT
    $SWAV
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Director Moll Frederic H bought $785,138 worth of shares (20,000 units at $39.26), increasing direct ownership by 2% to 863,159 units (SEC Form 4)

    4 - PROCEPT BioRobotics Corp (0001588978) (Issuer)

    8/14/25 4:18:26 PM ET
    $PRCT
    Medical/Dental Instruments
    Health Care

    SEC Form 10-Q filed by PROCEPT BioRobotics Corporation

    10-Q - PROCEPT BioRobotics Corp (0001588978) (Filer)

    8/7/25 4:39:41 PM ET
    $PRCT
    Medical/Dental Instruments
    Health Care

    PROCEPT BioRobotics Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - PROCEPT BioRobotics Corp (0001588978) (Filer)

    8/6/25 4:09:18 PM ET
    $PRCT
    Medical/Dental Instruments
    Health Care

    PROCEPT BioRobotics Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - PROCEPT BioRobotics Corp (0001588978) (Filer)

    7/24/25 6:42:16 PM ET
    $PRCT
    Medical/Dental Instruments
    Health Care

    PROCEPT BioRobotics Reports Second Quarter 2025 Financial Results and Increases 2025 Revenue Guidance

    SAN JOSE, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (NASDAQ:PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today reported unaudited financial results for the quarter ended June 30, 2025. Recent Highlights Total revenue of $79.2 million for the second quarter of 2025, an increase of 48% compared to the prior year period in 2024U.S. handpiece and consumables revenue of $43.1 million for the second quarter of 2025, an increase of 58% compared to the prior year period in 2024Sold 51 robotic systems in the U.S. in the second quarter of 2025U.S. system and rental revenue o

    8/6/25 4:03:00 PM ET
    $PRCT
    Medical/Dental Instruments
    Health Care

    PROCEPT BioRobotics® President and CEO Dr. Reza Zadno to Retire, Company Appoints Larry L. Wood as New President and CEO

    Larry L. Wood to join PROCEPT BioRobotics effective September 2, 2025Company confirms strong underlying business trends and pre-announces 2Q25 revenue of approximately $79.2 million, representing annual growth of 48% SAN JOSE, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics (NASDAQ:PRCT) ("the Company"), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced that Larry L. Wood will join the Company as president and CEO effective September 2, 2025. Dr. Reza Zadno will retire as president, CEO, and director effective September 1, 2025. Since 2020, Dr. Zadno has led the Company through significant growth

    7/24/25 6:00:00 PM ET
    $PRCT
    Medical/Dental Instruments
    Health Care

    Ambulatory Surgery Center Completes WATER IV Trial Procedures for Prostate Cancer with Aquablation® Therapy

    SAN JOSE, Calif., July 23, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (NASDAQ:PRCT) (the "Company"), a surgical robotics company dedicated to advancing patient care through transformative urology solutions, today announced that three prostate cancer procedures in the WATER IV Prostate Cancer (PCa) Trial were successfully completed in an Ambulatory Surgery Center (ASC) using Aquablation® therapy by Dr. Rahul Mehan of East Valley Urology in Scottsdale, Arizona. WATER IV PCa is a U.S. FDA investigational device exemption (IDE) approved clinical study comparing Aquablation® therapy and radical prostatectomy for the treatment of localized prostate cancer. The study will evalua

    7/23/25 8:00:00 AM ET
    $PRCT
    Medical/Dental Instruments
    Health Care

    $ISRG
    $PRCT
    $SWAV
    Financials

    Live finance-specific insights

    View All

    PROCEPT BioRobotics Reports Second Quarter 2025 Financial Results and Increases 2025 Revenue Guidance

    SAN JOSE, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (NASDAQ:PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today reported unaudited financial results for the quarter ended June 30, 2025. Recent Highlights Total revenue of $79.2 million for the second quarter of 2025, an increase of 48% compared to the prior year period in 2024U.S. handpiece and consumables revenue of $43.1 million for the second quarter of 2025, an increase of 58% compared to the prior year period in 2024Sold 51 robotic systems in the U.S. in the second quarter of 2025U.S. system and rental revenue o

    8/6/25 4:03:00 PM ET
    $PRCT
    Medical/Dental Instruments
    Health Care

    Intuitive Announces Second Quarter Earnings

    SUNNYVALE, Calif., July 22, 2025 (GLOBE NEWSWIRE) -- Intuitive (the "Company") (NASDAQ:ISRG), a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, today announced financial results for the quarter ended June 30, 2025. Q2 Highlights Worldwide da Vinci procedures grew approximately 17% compared with the second quarter of 2024.The Company placed 395 da Vinci surgical systems, compared with 341 in the second quarter of 2024. The second quarter 2025 da Vinci surgical system placements included 180 da Vinci 5 systems, compared with 70 in the second quarter of 2024.The Company grew its da Vinci surgical system installed base to 10,488 systems as of

    7/22/25 4:05:00 PM ET
    $ISRG
    Industrial Specialties
    Health Care

    PROCEPT BioRobotics® to Report Second Quarter 2025 Financial Results on August 6, 2025

    SAN JOSE, Calif., July 21, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (the "Company") (NASDAQ:PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced it will report financial results for the second quarter of 2025 after market close on Wednesday, August 6, 2025. The Company's management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by following one of the below links: Webcast link for interested listeners: https://edge.media-server.com/mmc/p/apg8aowj Dial-in registration for sell-side research a

    7/21/25 4:03:00 PM ET
    $PRCT
    Medical/Dental Instruments
    Health Care

    $ISRG
    $PRCT
    $SWAV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by PROCEPT BioRobotics Corporation

    SC 13G/A - PROCEPT BioRobotics Corp (0001588978) (Subject)

    11/14/24 1:28:32 PM ET
    $PRCT
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by PROCEPT BioRobotics Corporation

    SC 13G/A - PROCEPT BioRobotics Corp (0001588978) (Subject)

    11/12/24 5:01:10 PM ET
    $PRCT
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by PROCEPT BioRobotics Corporation

    SC 13G/A - PROCEPT BioRobotics Corp (0001588978) (Subject)

    11/4/24 1:31:19 PM ET
    $PRCT
    Medical/Dental Instruments
    Health Care

    $ISRG
    $PRCT
    $SWAV
    Leadership Updates

    Live Leadership Updates

    View All

    30 years of Innovation and Impact: Dan Larson's Inspiring Story

    SUNNYVALE, Calif., May 27, 2025 (GLOBE NEWSWIRE) -- When Seattle resident Dan Larson was diagnosed with lung cancer in 2023, his only exposure to robotic technology was through his work as a quality engineer at Boeing. He could never have imagined that robotic technology made by Intuitive, the pioneer of robotic-assisted surgery, would one day play a pivotal role in his health care. Having experienced the loss of his father to lung cancer, Dan was determined to overcome his own diagnosis and enjoy his retirement with his family. Under the care of clinicians at MultiCare Tacoma General Hospital in Washington, Dan underwent two robotic lung biopsies with the Ion Endoluminal System, Intuit

    5/27/25 9:15:00 AM ET
    $ISRG
    Industrial Specialties
    Health Care

    Intuitive Announces CEO Transition Effective July 1, 2025

    President Dave Rosa promoted to CEOCurrent CEO Gary Guthart to become executive chair of Intuitive's boardCurrent Board Chair Craig Barratt to become lead independent director SUNNYVALE, Calif., May 15, 2025 (GLOBE NEWSWIRE) -- Intuitive (NASDAQ:ISRG), a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, today announced the promotion of President Dave Rosa to chief executive officer, effective July 1, 2025. At that time, current CEO Gary Guthart will become the executive chair of Intuitive's board of directors, and current Board Chair Craig Barratt will become lead independent director. Guthart will work closely with Rosa to support a smooth t

    5/15/25 9:05:00 AM ET
    $ISRG
    Industrial Specialties
    Health Care

    DoorDash, TKO Group Holdings, Williams-Sonoma and Expand Energy Set to Join S&P 500; Others to Join S&P 100, S&P MidCap 400 and S&P SmallCap 600

    NEW YORK, March 7, 2025 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 100, S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, March 24, to coincide with the quarterly rebalance. The changes ensure each index is more representative of its market capitalization range. All companies being added to the S&P 100 are more representative of the mega-cap market space. All companies being added to the S&P 500 are more representative of the large-cap market space, all companies being added to the S&P MidCap 400 are more representative of the mid-cap market space, and all companies being added to the S&P

    3/7/25 6:19:00 PM ET
    $ALK
    $AMBC
    $ATI
    Air Freight/Delivery Services
    Consumer Discretionary
    Property-Casualty Insurers
    Finance